Sobi and Biogen's Elocta approved in Europe for hemophilia A

24 November 2015

The European Commission has approved Elocta (rFVIIIFc) for the treatment of hemophilia A in all 28 European Union member states, as well as Iceland, Liechtenstein and Norway.

Elocta, a recombinant factor VIII Fc fusion protein with an extended half-life, developed by Swedish Orphan Biovitrum (STO: SOBI) and US biotech firm Biogen (Nasdaq: BIIB), will be the first hemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.

"The EC`s approval of Elocta is an important milestone for the global hemophilia A community, offering the potential to improve the care of hemophilia A across the EU," said Birgitte Volck, senior vice president of development and chief medical officer of Sobi, adding: "Our focus is now to ensure timely and sustainable access to Elocta for people living with hemophilia A throughout Europe."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK